IMPACT WITH LONG-ACTING INJECTABLES. We develop a portfolio of long-acting injection products in various therapeutic areas by combining our BEPO® proprietary technology with existing and already-marketed active pharmaceutical ingredients. Our most advanced products, which address the treatment of schizophrenia and postoperative orthopedic pain, are respectively in a Phase 3 and Phase 2 clinical trial in the United States. Corporate presentation LATEST NEWS MEDINCELL RECEIVES €4 MILLION IN FUNDING FROM BPIFRANCE AND WITHIN THEFRAMEWORK OF THE FRENCH RECOVERY PLAN (PLAN FRANCE RELANCE) Read full story STOCK INFORMATION DATE OF THE IPO OCTOBER 8, 2018 ISIN CODE / TICKER FR0004065605 / MEDCL LISTED ON EURONEXT PARIS / B COMPARTMENT FINANCIAL YEAR CLOSING DATE MARCH 31 NUMBER OF SHARES (OCTOBER 31, 2021) 24,887,908 LIQUIDITY PROVIDER KEPLER CHEUVREUX ANALYSTS BRYAN GARNIER & CO, ERIC LE BERRIGAUD KEPLER CHEUVREUX, ARSÈNE GUEKAM ODDO-BHF The analysts listed above follow MedinCell. Any opinions, estimates or forecasts regarding MedinCell’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of MedinCell or its management. MedinCell does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analysts and institutions. Shareholding structure Founder (Nguyen Family) Collaborators and affiliates (management employees & consultants) Former collaborators & historical shareholders Other 19% 14% 41% 26% NEWS Videoconference and publication of the 2021-2022 Half-Year Results, on December 8, 2021 12.02.2021 MedinCell receives €4 million in funding from Bpifrance and within the framework of the French Recovery Plan (Plan France Relance) 12.01.2021 Phase 3 data of mdc-IRM, first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia: Prolonged time to impending relapse / Decreased risk of relapse / Increased chance of clinical stability 11.01.2021 MedinCell announces participation in the Jefferies London Healthcare Conference 2021 10.25.2021 MedinCell: mdc-IRM’s Phase 3 data to be presented for the first time by Teva at Psych Congress 2021 10.21.21 MedinCell releases the results of its September 9, 2021 ordinary annual and extraordinary general meeting 09.10.2021 MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM 09.01.2021 Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia 08.31.2021 Participation terms in the MedinCell Combined General Meeting 08.04.2021 See all GENERAL MEETING ARCHIVES Sept. 2021 General Meeting Thursday, September 9 2021 DOCUMENTATION Regulated information URD 2020/2021 (French) - 07.28.2021 Half-year liquidity contract statement Half-year liquidity contract statement - 01.13.2020 See all Videoconference, November 2, 2021 mdc-IRM Phase 3 results Transcript Replay video conference See all Presentations Corporate Presentation • September 2021 Corporate Presentation - June 2021 Corporate presentation - February 2021 See all Shares and voting rights FINANCIAL CALENDAR 2021 June 16, 2021 Annual results 2020-2021 (Apr. 2020 > Mar. 2021) Add to calendar September 9, 2021 General Meeting Add to calendar December 8, 2021 Half-Year results (Apr. > Sept. 2021) Add to calendar 2020 2019 2018 GOVERNANCE SUPERVISORY BOARD Anh Nguyen Chairman Sabri Markabi Vice-Chairman Philippe Guy Virginie Lleu Karine Lignel Representative of CM-CIC Innovation Elisabeth Kogan MANAGEMENT Christophe Douat CEO Franck Pouzache Chief People Officer Jaime Arango Chief Financial Officer Joël Richard Chief Development Officer Helen Martin Head of Alliance Management Adolfo Lopez Noriega Research Director Christophe Roberge Chief Technical Officer Quiterie De Beauregard Head of Portfolio David Heuzé Head of Communication CONTACTS Communication leader MedinCell David Heuzé david.heuze@medincell.com +33 (0)6 83 25 21 86 Investor Relations NewCap Louis-Victor Delouvrier / Mathilde Bohin medincell@newcap.eu +33 (0)1 44 71 94 94 Media NewCap Nicolas Merigeau medincell@newcap.eu +33 (0)1 44 71 94 94 © 2019 Medincell